[Hopespringpcsg] FW: This Week in Advanced Prostate Cancer

[Glen Tolhurst]

Hi all:

See below for several PCa related articles.

Thx to Michael Wilson for sharing them.

Take care,

Glen

 

 


	

 





Week in Review 


Advanced Prostate Cancer 

 <http://links.mkt1881.com/ctt?kn=6&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0>  <http://links.mkt1881.com/ctt?kn=6&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> Practice Update <http://links.mkt1881.com/ctt?kn=6&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> 

	

 


	

  <https://d2ogjlfjkptkow.cloudfront.net/punewsletter/general/ad-notice.gif> 


 <http://pubads.g.doubleclick.net/gampad/jump?co=1&iu=/6053/els.pracupadvancedprostatecancer/email/weekinreview&sz=728x90&t=day%3D20%26month%3D07%26year%3D2018> 

	

 


	


 <http://links.mkt1881.com/ctt?kn=11&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial 
2018 Jul 16 

  _____  

 <http://links.mkt1881.com/ctt?kn=3&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> New-Onset Diabetes After Androgen-Deprivation Therapy for Prostate Cancer: A Nationwide Propensity Score-Matched Four-Year Longitudinal Cohort Study 
2018 Jul 16 

  _____  

 <http://links.mkt1881.com/ctt?kn=10&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> The Androgen Receptor Inhibitor Enzalutamide Is Approved for Castration-Resistant, Nonmetastatic Prostate Cancer 
2018 Jul 19 

Commentary by Brian Lewis MD, MPH 

	

 




You're receiving this newsletter because you subscribed to Advanced Prostate Cancer : Week in Review 



	

 





 <http://links.mkt1881.com/ctt?kn=12&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> facebook 

	


 <http://links.mkt1881.com/ctt?kn=9&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> twitter 

	


 <http://links.mkt1881.com/ctt?kn=7&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> google+ 

	


 <http://links.mkt1881.com/ctt?kn=8&ms=NTcwMzE0MDcS1&r=MzQzMzY2NTY4OTMxS0&b=0&j=MTQ0MjQ0NDA0MAS2&mt=2&rj=MTQ0MjQ0NDA0MAS2&rt=0> LinkedIn 

	

 




 Brought to you by Elsevier <https://d2ogjlfjkptkow.cloudfront.net/punewsletter/general/elsevier-logo.gif> 
PracticeUpdate ® is a registered trademark of Elsevier Inc. 
Copyright © 2018, Elsevier Inc. All rights reserved. 
Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1800. Philadelphia, PA 19103-2899, USA 

	

  <http://open.mkt1881.com/open/log/57031407/MzQzMzY2NTY4OTMxS0/0/MTQ0MjQ0NDA0MAS2/2/MTQ0MjQ0NDA0MAS2/0> 

 

  <https://87tbwoak.emltrk.com/87tbwoak?d=192804> 

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://artsservices.uwaterloo.ca/pipermail/hopespringpcsg/attachments/20180728/6a258d16/attachment-0001.html>